Symbols

SGHT

Sight Sciences·NASDAQ

--(--)

SGHT fundamentals

SGHT Q4 2025 Earnings

Sight Sciences (SGHT) released its earnings on Mar 4, 2026: revenue was 20.39M (YoY +6.87%), beat estimates; EPS was -0.08 (YoY +65.22%), beat estimates.

Revenue / YoY

20.39M

+6.87%

EPS / YoY

-0.08

+65.22%

Report date

Mar 4, 2026

SGHT Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 total revenue $20.4 million (+7% YoY), driven by interventional glaucoma ($19.7M, +5%) and dry eye ($0.7M, +133%).
Dry Eye Breakthrough: $0.7M Q4 revenue with 700 SmartLid sales; two MACs establish reimbursement, enabling reimbursed market expansion.
Glaucoma Resilience: 5% YoY growth despite LCD headwinds; Omni Edge ASP growth and standalone market focus.
2026 Outlook: Revenue guidance $82-88M (+6-14%), with dry eye targeting $5-7M. Operating expenses $93-96M (+6-9%) for commercial scaling.
Key Risk: Q1 2026 low single-digit growth due to weather; long-term focus on standalone glaucoma and reimbursed dry eye.

Earnings

EPS

Revenue

Revenue & Expenses

SGHT has released its 2025 Q4 earnings report, with revenue of 20.39M, reflecting a YoY change of 6.87%, and net profit of -4.16M, showing a YoY change of 64.87%. The Sankey diagram below clearly presents SGHT's revenue sources and cost distribution.

Key Indicators

Sight Sciences (SGHT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Sight Sciences (SGHT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Sight Sciences (SGHT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Sight Sciences (SGHT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown